Karyopharm Therapeutics reported $301.57M in Debt for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Acceleron Pharma XLRN:US $ 0M 0M
Amgen AMGN:US $ 37579M 4797M
AstraZeneca AZN:LN 31912M 4417M
Astrazeneca AZN:US $ 31912M 4417M
Avrobio Inc AVRO:US $ 0 0
Biocryst Pharmaceuticals BCRX:US $ 304.16M 10.51M
Bristol Myers Squibb BMY:US $ 44742M 416M
Eli Lilly And LLY:US $ 17085.4M 570.3M
Enanta Pharmaceuticals ENTA:US $ 1.51M 0.03M
Epizyme EPZM:US $ 231.84M 0.64M
GlaxoSmithKline GSK:LN 25605M 122M
Karyopharm Therapeutics KPTI:US $ 301.57M 195K
Macrogenics MGNX:US $ 0M 0M
Mirati Therapeutics MRTX:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Novartis NOVN:VX SF 34243M 1526M
Novartis NVS:US $ 34243M 1526M
Regeneron Pharmaceuticals REGN:US $ 2698.6M 1M
Sangamo Biosciences SGMO:US $ 0M 0M
Takeda 4502:JP Y 4231359M 174502M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
Xencor XNCR:US $ 0M 0M
YTE INCY:US $ 33.78M 0.47M